News
-
-
PRESS RELEASE
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
UCB presents positive results from GEMZ phase 3 study at AES showing significant reduction in countable motor seizure frequency in CDKL5 Deficiency Disorder. Study demonstrates efficacy and safety of fenfluramine as adjunctive treatment